Kevin C. Zorn, MD, FACS, FRCSC

Kevin C. Zorn, MD, FACS, FRCSC

BPH Canada Prostate Institute

Montréal, Québec, Canada

Kevin C. Zorn, MD, FACS, FRCSC, is the Founder and Director at BPH Canada Prostate Institute in Montréal, Canada. Dr. Zorn also serves as Director of Urology and BPH Prostate MIS Surgery at the Centre de chirurgie Mont-Royal. His main focus of clinical and scientific interest is the surgical treatment of renal and prostate cancer. He is also an expert in performing surgery with the daVinciⓇ Surgical Robotic System to manage localized prostate cancer and small renal masses.

Dr. Zorn attended McGill University in Montréal for his pre-med program, his medical degree, and his residency in Urological Surgery. He became a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a fellowship in oncology and endourology at the University of Chicago. In 2007, he became certified by the American Board of Urology in urology and a Fellow of the American College of Surgeons.

Dr. Zorn was the first in Canada to use many new BPH technologies, including Greenlight XPS, Rezum, iTind, Optilume, Aquablation, and Zenflow. He has also been the first in Canada to introduce cutting-edge technologies, including the Clarius and ButterflyIQ point-of-care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and greater safety. Dr. Zorn is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques. 

Dr. Zorn is the senior author of the Male Lower Urinary Tract Symptoms (LUTS)/BPH Guidelines for the 2018 and 2022 Canadian Urological Association (CUA) and consulted on the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation, as well as the CUA BPH patient decision-aid tool. Dr. Zorn has authored 400 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care.

Talks by Kevin C. Zorn, MD, FACS, FRCSC

BPH Mist Options: Rezum & Stents

BPH Mist Options: Rezum & Stents

| Sep 2024

Kevin C. Zorn, MD, FACS, FRCSC, addresses the challenges and advancements in managing benign prostatic hyperplasia (BPH), focusing on minimally invasive surgical techniques. In this 17-minute presentation, he highlights the limitations of traditional treatments, such as transurethral resection of the prostate (TURP), and a growing demand for effective and less invasive alternative options.

Dr. Zorn explores the evolution of BPH treatments, discussing the importance of finding office-based, quick, and cost-effective solutions. He describes various less invasive technologies, including UroLift, Rezūm, and novel stent devices like iTind and Optilume.

Zorn underscores the variability in patient outcomes based on prostate anatomy and tissue composition, noting the importance of personalized treatment approaches. Moving towards a more tailored approach, similar to the precision seen in prostate cancer management, considers prostate size and tissue composition.

Read More
Overview of Current MIST: Practical Considerations

Overview of Current MIST: Practical Considerations

| Aug 2024

Kevin C. Zorn, MD, FRCSC, FACS, provides an authoritative overview of current minimally invasive surgical techniques (MIST) for the treatment of benign prostatic hyperplasia (BPH). His analysis emphasizes the advancements in MIST and their role in providing effective and patient-friendly alternatives to traditional surgical approaches.

Dr. Zorn highlights the primary MIST options currently available, including transurethral resection of the prostate (TURP), photoselective vaporization of the prostate (PVP), holmium laser enucleation of the prostate (HoLEP), and newer techniques such as water vapor thermal therapy and prostatic urethral lift (PUL). The procedural nuances of each MIST option are discussed in detail.

Dr. Zorn examines the outcomes and benefits of MIST as well as the challenges and limitations of the procedures. Future directions in MIST are considered, with Dr. Zorn highlighting ongoing research and innovation to further refine these techniques and expand their applicability. The integration of advanced imaging technologies and the development of novel therapeutic devices hold promise for enhancing the precision and effectiveness of MIST.

Read More
Water Vapor Thermal Therapy. How I Do It

Water Vapor Thermal Therapy. How I Do It

| Aug 2024

Kevin C. Zorn, MD, FRCSC, FACS, analyzes water vapor thermal therapy for the treatment of benign prostatic hyperplasia (BPH), focusing on its application, benefits, and procedural techniques. His discussion highlights the efficacy and minimally invasive nature of this therapy, making it an appealing option for patients seeking relief from BPH symptoms.

Dr. Zorn explains the mechanism of water vapor thermal therapy, which involves the delivery of steam directly into the prostate tissue. He outlines the procedural steps, starting with patient preparation and anesthesia. Dr. Zorn details the insertion of the transurethral device and the precise delivery of water vapor to the targeted prostate zones.

The advantages of water vapor thermal therapy are discussed extensively. Dr. Zorn highlights its high safety profile, low risk of complications, and significant improvement in urinary symptoms and quality of life. He also notes the durability of the treatment outcomes. Challenges and potential complications are addressed, including transient dysuria, hematuria, and urinary retention.

Future directions for water vapor thermal therapy include ongoing research to refine techniques, improve patient outcomes, and expand the indications for this treatment. Dr. Zorn highlights the potential for combining this therapy with other minimally invasive treatments to enhance efficacy and broaden its applicability.

Read More